The poor prognosis associated with MCL1 amplification or overexpression has been described in a spectrum of cancers, including non-small cell lung cancer, breast cancer, esophageal squamous cell carcinoma, and acute myeloid leukemia, but not in glioma (49–52). The gene discussed is MCL1; the disease is central nervous system cancer.